News

Rezpeg tamps down disease activity; fails to meet ISLAND primary goal

A middle dose of rezpegaldesleukin, an experimental medicine being developed by Nektar Therapeutics, led to clinically meaningful gains in measures of disease activity in people with systemic lupus erythematosus (SLE). That’s according to top-line data from ISLAND (NCT04433585), a Phase 2 clinical study that evaluated how safe…

SLE patients may have reduced response to COVID-19 vaccination

Patients with systemic lupus erythematosus (SLE) have a reduced response to COVID-19 vaccination, an effect made worse by specific immunosuppressive treatments, a recent study reports. A reduced response was demonstrated by lower levels of immunoglobulin G (IgG) against the spike protein of SARS-CoV-2, the virus that causes COVID-19. IgG…

SLE patients carry unique mix of tongue bacteria: Study

People with systemic lupus erythematosus (SLE) have a unique mix of bacteria on their tongue compared with healthy people, according to a Chinese study. Bacteria diversity correlated with disease activity, but also with recovery after treatment. The findings suggest oral bacteria “may be a therapeutic target for exploring new…

Better measures of disease severity needed in lupus, study says

New measures are needed to assess disease severity in lupus in clinical trials, a study highlights. One important goal in developing such measures is to include patient-reported outcomes — which, according to the study authors, are now not used in most clinical trials assessing the effectiveness of new treatments.

Black SLE patients at 19 times higher risk of early heart disease

Black people with systemic lupus erythematosus (SLE) are at a higher risk of developing heart disease — especially in the early years after their diagnosis — compared with non-Black patients, a new U.S. study found. The risk of cardiovascular disease or CVD was particularly elevated in the first 12…

Saphnelo linked to reaching low disease activity status in SLE

Adding Saphnelo (anifrolumab-fnia) to standard therapy in people with moderate to severe systemic lupus erythematosus (SLE) is linked to reaching a state of low disease activity faster and more frequently, according to an analysis of data from two Phase 3 clinical trials. This low disease activity state was sustained for…